SCHEMBL4708484

SCHEMBL4708484

CCn1nc(-c2ccccc2)c(C(=O)OCc2ccccc2)c(Nc2cccc(Cl)c2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.52
ACHE P22303 1/20 0.45
BACE1 P56817 1/20 0.45
PARP1 P09874 2/20 0.44
PDE4A P27815 3/20 0.44
PDE4C Q08493 3/20 0.44
PDE4D Q08499 3/20 0.44
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
ALOX5 P09917 1/20 0.41
PTGES O14684 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707603 0.92 PDE4B (0.55) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4708343 0.90 PDE4B (0.56) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4706084 0.87 PDE4B (0.62) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4707950 0.86 PDE4B (0.55) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4058811 0.86 PDE4B (0.70) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4706418 0.85 PDE4B (0.60) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4705601 0.85 PDE4B (0.53) PDE4BACHEBACE1PARP1PDE4A
SCHEMBL4707878 0.85 PDE4B (0.53) PDE4BACHEBACE1PARP1MAPT
SCHEMBL4050336 0.85 PDE4B (0.53) PDE4BPDE4APDE4CPDE4DTP53
SCHEMBL4706645 0.83 PDE4B (0.56) PDE4BACHEBACE1PARP1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.